Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2019

Francoise Farace's Biography



Francoise Farace, Head of Rare Circulating Cells Translational Laboratory, INSERM Gustave Roussy Institute

Françoise Farace is currently in charge of the Translational Laboratory of Rare Circulating Cells at CNRS UMS3655 - INSERM US23 AMMICA, and of the Circulating Tumor Cells team at INSERM U981, Gustave Roussy. FF has obtained a PhD degree in Pharmacology at Paris University VI, and HDR (Habilitation à Diriger des Recherches) at Paris University XI. FF has been in charge of several programs in immunotherapy, gene and cellular therapy at Gustave Roussy. From 2002 to 2005, FF was President of the board and R &D Director of the Biotech company “C.I.L Technologies” (Free University of Brussels). For the past twelve years, FF focused her research on rare circulating cells such as circulating endothelial cells and circulating tumor cells with the goal of identifying both sensitivity and resistance biomarkers of anticancer therapies. FF has authored over 90 peer-reviewed publications.

Francoise Farace Image

CTC Genetic Diversity Through Single-Cell Analysis and CDX Development

Wednesday, 30 October 2019 at 16:15

Add to Calendar ▼2019-10-30 16:15:002019-10-30 17:15:00Europe/LondonCTC Genetic Diversity Through Single-Cell Analysis and CDX DevelopmentCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Tyrosine kinase inhibitors (TKIs) tailored for oncogenic driver alterations have shown unprecedented success in patients harboring EGFR-mutations, ALK- or ROS1-gene rearrangements. However the long-term effectiveness of TKIs is invariably limited by the development of resistance. CTCs are a powerful means to identify genetic alterations predictive of sensitivity or resistance to TKIs, inform on tumor heterogeneity and resistance mechanism, and the characteristics of cancer cells with metastatic potential. Using filter-adapted FISH, we reported ALK-rearrangement detection in CTCs from ALK-rearranged patients and how CTCs with abnormal ALK FISH-patterns monitored on treatment can stratify patients at risk of early-resistance to first-line ALK inhibitor crizotinib. Recently, we developed several workflows enabling to identify resistance mutations to ALK-inhibitors. Individual CTCs were isolated by laser-microdissection of filters, fluorescence-activated cell sorting or the DEPArray, and tested for more than 2000 hotspots in cancer oncogenes and ALK-mutations. Shared mutations between CTCs and tumor biopsies at resistance to crizotinib and lorlatinib (third generation ALK inhibitor) and CTC-private (exclusively present in CTCs) mutations were thoroughly explored (Pailler et al, in revision).

CTC-derived explant (CDX) model are useful tools to explore drug resistance and improve knowledge on the genetic and phenotypical profile of CTCs that seed metastasis. Our team has recently conducted a project to develop and functionally characterize CDXs in two tumors types i.e. NSCLC and prostate cancer (PCa). In PCa, we established and completed the genetic characterization of a CDX model which was found to recapitulate a mechanism of neuroendocrine transdifferentiation and resistance to therapies targeting the androgen receptor pathway (Faugeroux et al., in revision). These results will be presented at the conference.


Add to Calendar ▼2019-10-30 00:00:002019-11-01 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com